| TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention (NCT04294927) | University Medical Center Nijmegen | 2020-03-01 |
| Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects (NCT04030559) | University of California, Davis | 2020-02-25 |
| Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery (NCT03943173) | M.D. Anderson Cancer Center | 2019-06-07 |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency (NCT03442556) | University of Washington | 2018-08-24 |
| Usefulness of Video-Based Intervention in Helping Participants Encourage Their Families to Get Tested for BRCA Gene Mutations (NCT05264532) | Ohio State University Comprehensive Cancer Center | 2018-04-05 |
| Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability (NCT03428802) | Rutgers, The State University of New Jersey | 2018-03-08 |
| Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation (NCT02953457) | Roswell Park Cancer Institute | 2017-06-29 |
| Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068) | M.D. Anderson Cancer Center | 2017-04-18 |
| Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer (NCT03377556) | SWOG Cancer Research Network | 2017-03-03 |
| Pancreatic Cancer Screening of High-Risk Individuals in Arkansas (NCT02309632) | University of Arkansas | 2015-11-01 |
| The Link Between BRCA Mutation and Endothelial Function (NCT02474264) | Rabin Medical Center | 2015-02-01 |
| Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers (NCT02321228) | University Medical Center Nijmegen | 2015-01-01 |
| Cancer Prevention in Women With a BRCA Mutation (NCT02225015) | Women's College Hospital | 2015-01-01 |
| Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes (NCT02286687) | M.D. Anderson Cancer Center | 2014-12-22 |
| A Nutritional Intervention to Decrease Breast Density Among Female BRCA (BReast CAncer Susceptibility Gene) Carriers (NCT02197000) | Rabin Medical Center | 2014-11-11 |
| Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members (NCT02194387) | M.D. Anderson Cancer Center | 2014-09-17 |
| Prospective Research of Outcomes After Salpingo-oophorectomy (NCT01948609) | University of California, San Francisco | 2014-07-01 |
| A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients (NCT01905592) | Tesaro, Inc. | 2014-02-25 |
| Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells (NCT01907438) | Hadassah Medical Organization | 2013-09-01 |
| Pilot Study of Curcumin for Women With Obesity and High Risk for Breast Cancer (NCT01975363) | Ohio State University Comprehensive Cancer Center | 2013-06-01 |